Valuation: Fennec Pharmaceuticals Inc.

Market Cap 380M 329M 308M 281M 530M 36.24B 538M 3.61B 1.41B 18.13B 1.43B 1.4B 60.39B P/E 2026 *
41.8x
P/E 2027 * 11.6x
Enterprise Value 380M 329M 308M 281M 530M 36.24B 538M 3.61B 1.41B 18.13B 1.43B 1.4B 60.39B EV / Sales 2026 *
5.44x
EV / Sales 2027 * 3.78x
Free-Float
80.22%
Yield 2026 *
-
Yield 2027 * -
1 day-4.28%
1 week+2.87%
Current month+9.15%
1 month-4.79%
3 months+51.69%
6 months+38.76%
Current year+43.20%
1 week 8.05
Extreme 8.05
9.9
1 month 7.85
Extreme 7.85
9.9
Current year 4.74
Extreme 4.74
9.9
1 year 4.74
Extreme 4.74
9.9
3 years 3.68
Extreme 3.68
10.4
5 years 3.36
Extreme 3.36
10.4
10 years 1.48
Extreme 1.482
14.92
Manager TitleAgeSince
Chief Executive Officer 64 16/08/2024
Director of Finance/CFO 51 06/01/2010
Chief Tech/Sci/R&D Officer 51 28/10/2024
Director TitleAgeSince
Director/Board Member 72 25/08/2011
Chairman 69 09/12/2015
Director/Board Member 70 10/08/2016
Change 5-day change 1-year change 3-year change Capi.($)
-4.28%+2.87% - - 380M
+3.90%+9.86%+96.91%+136.30% 1,098B
+0.99%+2.91%+51.05%+52.06% 631B
+0.78%+1.17%+25.21%+63.74% 438B
-0.16%+4.17%+51.28%+40.52% 368B
+0.02%+1.78%+32.08%+39.70% 298B
-0.63%+1.28%+7.74%+7.80% 251B
+1.52%+10.12%+44.75%+59.20% 226B
+0.74%+0.28%-4.39%-50.30% 209B
-0.11%+1.46%+11.43%+66.32% 165B
Average -0.38%+1,657.21%+35.12%+46.15% 409.37B
Weighted average by Cap. -0.04%+1,331.50%+51.87%+68.65%

Financials

2026 *2027 *
Net sales 69.83M 60.45M 56.5M 51.64M 97.31M 6.66B 98.83M 663M 260M 3.33B 262M 256M 11.1B 100M 86.95M 81.28M 74.28M 140M 9.58B 142M 953M 374M 4.79B 377M 369M 15.96B
Net income 8.99M 7.78M 7.27M 6.65M 12.53M 857M 12.72M 85.3M 33.47M 429M 33.76M 33.02M 1.43B 33.1M 28.65M 26.78M 24.48M 46.13M 3.16B 46.85M 314M 123M 1.58B 124M 122M 5.26B
Net Debt - -
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change
11/08/26 8.950 -4.28%
10/08/26 €9.350 -5.56%
07/08/26 €9.900 +5.32%
06/08/26 €9.400 +5.03%
05/08/26 €8.950 +2.87%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.94USD
Average target price
15.67USD
Spread / Average Target
+43.21%

Quarterly revenue - Rate of surprise